Latest Breaking News On - Jubilant therapeutics - Page 6 : comparemela.com

Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors

Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors BEDMINSTER, N.J., Feb. 5, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced the addition of Robert Glassman, M.D., to the company s Board of Directors. Dr. Glassman will serve as an independent, non-executive director, effective February 1, 2021. Rob s experience and insights will bring new dimension to the company as we chalk our growth strategy and we warmly welcome him to our board, said Hari Bhartia, Chairman, Jubilant Therapeutics. Rob is a recognized leader in the biopharma industry and his oncology background and financial acumen will be invaluable as we execute on our strategic goals, said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics.

United statesAmericanHidesaburo hanafusaWeill cornellKostenloser wertpapierhandelSyed kazmiHari bhartiaRobert glassmanUmoja biopharmaGlobal investment banking group at credit suisseLinkedinHarvard medical schoolJubilant therapeutics incPrnewswire jubilant therapeutics incRockefeller universityHospital of the university pennsylvania

Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19

(1) BEDMINSTER, N.J., Jan. 15, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms. PAD4 is an enzyme that catalyzes conversion of arginine to citrulline in proteins, including histones and is highly expressed in neutrophils. Histone citrullination has been implicated in Neutrophil Extracellular Trap (NET) formation and accumulating evidence suggests that NETs may be linked to the severity of COVID-19, as their formation is a result of pro-inflammatory cytokine release syndrome (CRS), or cytokine storms, produced by the body s immune resp

United statesKostenloser wertpapierhandelSyed kazmiYulia nefedovaLinkedinNational cancer instituteCancer centerJubilant therapeutics incJubilant life sciencesPrnewswire jubilant therapeutics incWistar instituteMicroenvironment metastasis programTherapeutics incPeptidyl arginineJubilant therapeuticsNeutrophil extracellular trap

Exclusive | Jubilant Life Sciences Looking To Tap PE Funds For Pharma Business, Raise $500 Million

Exclusive | Jubilant Life Sciences Looking To Tap PE Funds For Pharma Business, Raise $500 Million
moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.

United statesHyderabadAndhra pradeshIndiaCanadaAmericaHaris bhartiaShyams bhartiaSuven pharmaBiocon biologicsBioconGoldman sachsJubilant life sciencesNational company law tribunalSuven life sciencesJubilant life sciences ltd